Smart Wearables for Cardiac Monitoring—Real-World Use beyond Atrial Fibrillation

Duncker, David; Ding, Wern Yew; Etheridge, Susan P.; Noseworthy, Peter A.; Veltmann, Christian; Yao, Xiaoxi; Bunch, T. Jared; Gupta, Dhiraj

doi:10.3390/s21072539

Cited by 81 publications

(47 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Step count monitoring is popular in the general population, using wearable devices such as smartphones, smartwatches, or wearable pedometers [ 43 ]. Just as described above for the resting heart rate, population-based cohort studies showed that a higher number of steps per day correlated with a lower mortality rate in a cohort of adults [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

Feasibility and First Results of Heart Failure Monitoring Using the Wearable Cardioverter–Defibrillator in Newly Diagnosed Heart Failure with Reduced Ejection Fraction

Hillmann

Hohmann

Mueller-Leisse

et al. 2021

Sensors

Self Cite

View full text Add to dashboard Cite

The wearable cardioverter–defibrillator (WCD) is used in patients with newly diagnosed heart failure and reduced ejection fraction (HFrEF). In addition to arrhythmic events, the WCD provides near-continuous telemetric heart failure monitoring. The purpose of this study was to evaluate the clinical relevance of additionally recorded parameters, such as heart rate or step count. We included patients with newly diagnosed HFrEF prescribed with a WCD. Via the WCD, step count and heart rate were acquired, and an approximate for heart rate variability (HRV5) was calculated. Multivariate analysis was performed to analyze predictors for an improvement in left ventricular ejection fraction (LVEF). Two hundred and seventy-six patients (31.9% female) were included. Mean LVEF was 25.3 ± 8.5%. Between the first and last seven days of usage, median heart rate fell significantly (p < 0.001), while median step count and HRV5 significantly increased (p < 0.001). In a multivariate analysis, a delta of HRV5 > 23 ms was an independent predictor for LVEF improvement of ≥10% between prescription and 3-month follow-up. Patients with newly diagnosed HFrEF showed significant changes in heart rate, step count, and HRV5 between the beginning and end of WCD prescription time. HRV5 was an independent predictor for LVEF improvement and could serve as an early indicator of treatment response.

show abstract

Section: Discussionmentioning

confidence: 99%

Feasibility and First Results of Heart Failure Monitoring Using the Wearable Cardioverter–Defibrillator in Newly Diagnosed Heart Failure with Reduced Ejection Fraction

Hillmann

Hohmann

Mueller-Leisse

et al. 2021

Sensors

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous research shows that only 20% of patients think there are more advantages than disadvantages in the application of AI, and 35% of participants would refuse to implement their disease-related intervention through AI [107]. Patients worry about losing connection with clinicians and are also concerned about the misuse of AI that can cause additional damage to their health, which may be caused by inadequate follow-up and insufficient education [108]. Achieving public trust is necessary to operate AI-based cardiac telerehabilitation [109].…”

Section: Trustworthiness and Willingness To Use Aspectsmentioning

confidence: 99%

Mobilizing artificial intelligence to cardiac telerehabilitation

Jin¹,

Zhang²,

Ke³

et al. 2022

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Cardiac telerehabilitation is a method that uses digital technologies to deliver cardiac rehabilitation from a distance. It has been shown to have benefits to improve patients' disease outcomes and quality of life, and further reduce readmission and adverse cardiac events. The outbreak of the coronavirus pandemic has brought considerable new challenges to cardiac rehabilitation, which foster cardiac telerehabilitation to be broadly applied. This transformation is associated with some difficulties that urgently need some innovations to search for the right path. Artificial intelligence, which has a high level of data mining and interpretation, may provide a potential solution. This review evaluates the current application and limitations of artificial intelligence in cardiac telerehabilitation and offers prospects.

show abstract

“…Nowadays, wearable devices—such as wrist bands and smartwatches—have biological sensors; thus, their complexity has not only the potential to track health, wellness, and fitness but also the potential to diagnose cardiovascular diseases. This can be prescribed by a health care provider and influence therapeutic decisions [ 91 ].…”

Section: Wearable Sensors In Health Monitoringmentioning

confidence: 99%

“Listen to Your Immune System When It’s Calling for You”: Monitoring Autoimmune Diseases Using the iShU App

Ortet

Costa

2022

Sensors

View full text Add to dashboard Cite

The immune system plays a key role in protecting living beings against bacteria, viruses, and fungi, among other pathogens, which may be harmful and represent a threat to our own health. However, for reasons that are not fully understood, in some people this protective mechanism accidentally attacks the organs and tissues, thus causing inflammation and leads to the development of autoimmune diseases. Remote monitoring of human health involves the use of sensor network technology as a means of capturing patient data, and wearable devices, such as smartwatches, have lately been considered good collectors of biofeedback data, owing to their easy connectivity with a mHealth system. Moreover, the use of gamification may encourage the frequent usage of such devices and behavior changes to improve self-care for autoimmune diseases. This study reports on the use of wearable sensors for inflammation surveillance and autoimmune disease management based on a literature search and evaluation of an app prototype with fifteen stakeholders, in which eight participants were diagnosed with autoimmune or inflammatory diseases and four were healthcare professionals. Of these, six were experts in human–computer interaction to assess critical aspects of user experience. The developed prototype allows the monitoring of autoimmune diseases in pre-, during-, and post-inflammatory crises, meeting the personal needs of people with this health condition. The findings suggest that the proposed prototype—iShU—achieves its purpose and the overall experience may serve as a foundation for designing inflammation surveillance and autoimmune disease management monitoring solutions.

show abstract

Smart Wearables for Cardiac Monitoring—Real-World Use beyond Atrial Fibrillation

Cited by 81 publications

References 146 publications

Feasibility and First Results of Heart Failure Monitoring Using the Wearable Cardioverter–Defibrillator in Newly Diagnosed Heart Failure with Reduced Ejection Fraction

Feasibility and First Results of Heart Failure Monitoring Using the Wearable Cardioverter–Defibrillator in Newly Diagnosed Heart Failure with Reduced Ejection Fraction

Mobilizing artificial intelligence to cardiac telerehabilitation

“Listen to Your Immune System When It’s Calling for You”: Monitoring Autoimmune Diseases Using the iShU App

Contact Info

Product

Resources

About